The North America Enteric Disease Testing Market would witness market growth of 2.6% CAGR during the forecast period (2023-2029).
Enteric diseases are tested commonly by two methods, molecular diagnostics and immunodiagnostics. The identification of strains and the isolation of intestinal pathogens are two microbiological applications of molecular diagnostics. Utilizing various molecular diagnostics approaches, disease-causing microbes are also researched. The advent of technologically advanced equipment with higher degrees of accuracy will likely lead to an increase in the use of molecular diagnostics in microbiology.
In addition, molecular diagnostics are used in clinical laboratories as a component of laboratory automation. As a result, the market for enteric disease testing is anticipated to grow throughout the projected period due to the increasing acceptance of molecular diagnostics testing methods.
Even in industrialized nations, enteric diseases with low infectious doses that allow effective person-to-person transmissions, like Shigella and noroviruses, provide a significant concern, particularly in crowded settings. For instance, communities with high levels of household congestion, like the ultraorthodox Jewish population, and children in childcare centers represent major high-risk groups for shigellosis.
The regional demand is driven by the presence of a refined reimbursement structure designed to reduce expenditure levels. In addition, the healthcare industry in this region has a strong infrastructure, with a high purchasing power and an increasing adoption pace of enteric disease testing. In the US, the Cholera and Other Vibrio Illness Surveillance (COVIS) system is a nationwide surveillance system that monitors human infection caused by pathogenic species of the Vibrionaceae family, known to cause cholera and vibriosis. According to the Centers for Disease Control and Prevention (CDC), COVIS reported a total of 1,252 cases of Vibrio infections in 2014. of these, 27% of the patients were hospitalized, and 4% passed away. Therefore, these elements are expected to contribute to the growth of the market.
The US market dominated the North America Enteric Disease Testing Market by Country 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,280.1 million by 2029. The Canada market is anticipated to grow at a CAGR of 4.9% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 4% during (2023 - 2029).
Based on End User, the market is segmented into Hospital Laboratories, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes. Based on Disease Type, the market is segmented into Bacterial, Viral and Parasitic. Based on Product Type, the market is segmented into Reagents & Consumables and Equipment. Based on Technique, the market is segmented into Immunodiagnostics and Molecular Diagnostics. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Enteric Disease Testing Market is Projected to reach USD 4.6 Billion by 2029, at a CAGR of 3.2%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., SGS S.A., Eurofins Scientific SE, Bureau Veritas S.A., Intertek Group PLC, TÜV Nord Group, PerkinElmer, Inc., Becton, Dickinson and Company and Neogen Corporation.
By End User
By Disease Type
By Product Type
By Technique
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 